COVID-19 Impact on Inovio Pharmaceuticals Inc.

Company Profile
29 Pages
July 2020
GlobalData
Inovio Pharmaceuticals Inc
ID: 5134500

Summary

This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Scope

The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
Inovio’s pipeline is most active in early-stage drug development
INO-4800 is Inovio’s COVID-19 vaccine
Funding from different sources for INO-4800

Reasons to Buy

An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.

1 Executive Summary

2 Company Overview

2.1 Key Stats
2.2 SWOT Analysis
2.3 Sales Forecast Overview

3 Regional Analysis

3.1 COVID-19 Spread vs. Location of Inovio Pharmaceuticals Inc. Trials
3.2 COVID-19 vs. Non-COVID-19 Trials

4 Reaction to COVID-19

4.1 INO-4800
4.2 Insight’s Exclusive Intel: Inovio Pharmaceuticals
4.3 Global Analyst Consensus Sales Forecast
4.4 Upcoming Events
4.5 Recent Deal Activity

5 Key Findings

6 Appendix

6.1 Methodology
6.2 About the Publisher
6.3 Contacts